We continued to investigate the therapeutic potential of blocking novel immune checkpoint molecules PVR and PVRL2 for hepatocellular carcinoma through in vitro immune cell mediated cytotoxicity assays. The gene discussed is PVR; the disease is hepatocellular carcinoma.